TCIM
AZN icon

TIAA CREF Investment Management’s AstraZeneca AZN Stock Holding History

TIAA CREF Investment Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$15.4M Sell
190,169
-81,352
-30% -$6.41M 0.01% 825
2018
Q4 		$20.6M Sell
271,521
-138,144
-34% -$10.8M 0.02% 635
2018
Q3 		$32.4M Buy
409,665
+163,409
+66% +$12.4M 0.02% 570
2018
Q2 		$17.3M Sell
246,256
-108,517
-31% -$7.81M 0.01% 817
2018
Q1 		$24.8M Sell
354,773
-75,769
-18% -$5.25M 0.02% 662
2017
Q4 		$29.9M Sell
430,542
-24,700
-5% -$1.67M 0.02% 606
2017
Q3 		$30.8M Sell
455,242
-38,660
-8% -$2.44M 0.02% 591
2017
Q2 		$33.7M Buy
493,902
+75,438
+18% +$4.93M 0.02% 557
2017
Q1 		$26.1M Buy
418,464
+148,780
+55% +$8.66M 0.02% 652
2016
Q4 		$14.7M Buy
269,684
+27,191
+11% +$1.54M 0.01% 896
2016
Q3 		$15.9K Buy
242,493
+33,850
+16% +$2.21M 0.01% 868
2016
Q2 		$12.6M Buy
208,643
+9,460
+5% +$549K 0.01% 936
2016
Q1 		$11.2M Buy
199,183
+62,033
+45% +$3.73M 0.01% 995
2015
Q4 		$9.31M Sell
137,150
-19,000
-12% -$1.25M 0.01% 1113
2015
Q3 		$9.94M Buy
156,150
+21,750
+16% +$1.43M 0.01% 1048
2015
Q2 		$8.56M Sell
134,400
-58,000
-30% -$3.97M 0.01% 1263
2015
Q1 		$13.2M Sell
192,400
-1,704,553
-90% -$118M 0.01% 972
2014
Q4 		$134M Buy
1,896,953
+1,535,585
+425% +$110M 0.09% 247
2014
Q3 		$25.8M Buy
361,368
+120,488
+50% +$8.82M 0.02% 681
2014
Q2 		$17.9M Sell
240,880
-24,651
-9% -$1.78M 0.01% 830
2014
Q1 		$17.2M Sell
265,531
-319,259
-55% -$20.6M 0.01% 842
2013
Q4 		$34.7M Sell
584,790
-58,282
-9% -$3.17M 0.02% 596
2013
Q3 		$33.4M Sell
643,072
-51,199
-7% -$2.57M 0.03% 583
2013
Q2 		$32.8M Buy
+694,271
New +$35.4M 0.03% 567

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TIAA CREF Investment Management's AZN Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its AstraZeneca (AZN) stake by 30% in Q1 2019, selling an estimated $6.41M and leaving 190,169 shares worth $15.4M. The position accounts for 0.01% of the portfolio, ranked #825.

TIAA CREF Investment Management first reported a position in AZN in Q2 2013 and has held it in 24 quarters since. The position peaked at $134M in Q4 2014. 559 funds tracked by Wall St. Rank hold AZN as of Q1 2019.

  • TIAA CREF Investment Management held 190,169 shares of AstraZeneca worth $15.4M as of Q1 2019.
  • TIAA CREF Investment Management sold 81,352 AstraZeneca shares in Q1 2019, an estimated $6.41M.
  • AstraZeneca made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #825 holding.
  • TIAA CREF Investment Management first reported a position in AstraZeneca in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's AstraZeneca position peaked at $134M in Q4 2014.
  • 559 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.